LY2090314
Cat. No.：YN420236
CAS No. ：603288-22-8
规格
价格(RMB)
库存
| 产品名称: | LY2090314 |
| CAS No.: | 603288-22-8 |
| Chemical Name: | 3-[9-fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1H-pyrrole-2,5-dione |
| Synonyms: | LY2090314;Kinome_3681;LY-2090314;3-[9-Fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1h-pyrrole-2,5-dione;3-[9-Fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro[1,4]diazepino[6, |
| 分子量: | 512.53 |
| 分子式: | C₂₈H₂₅FN₆O₃ |
| SMILES: | O=C(C(C1=CN2CCN(C(N3CCCCC3)=O)CC4=CC(F)=CC1=C42)=C5C6=CN=C7C=CC=CN76)NC5=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | LY2090314 是一种有效的GSK-3抑制剂，抑制 GSK-3α 和 GSK-3β，IC50值分别为 1.5 nM 和 0.9 nM。 |
| IC50和靶点: | [{name:"GSK-3β:0.9 nM (IC50)"},{name: "GSK-3α:1.5 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Atkinson, J.M., Rank, K.B., Zeng, Y., et al.Activating the Wnt/β-catenin pathway for the treatment of melanoma--application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3PLoS One2015,e0125028(2015)
Gray, J.E., Infante, J.R., Brail, L.H., et al.A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatinInvest New Drugs33(6),1187-1196(2015)
